title: [Could treatments with beta-blockers be associated with a reduction in cancer risk?].
abstract: BACKGROUND
  The relationship between the use of anti-hypertensive drugs and cancer risk remains controversial. The main objective of this study was to assess the potential effect of beta-blocker use on cancer risk.
  
  
  METHODS
  In a cohort of 839 patients with cardiovascular disease, followed up prospectively for an average period of 10 years, cancer occurrence was recorded according to the exposure to beta-blockers. The relative risk of cancer associated with beta-blocker use was estimated using a Cox model adjusted on gender and age. Ever- vs never-use of beta-blockers and duration of exposure to the drug were analyzed as time-dependent variables. In addition, the standardized incidence ratios (SIR) were calculated using the corresponding age- and gender-adjusted cancer incidences in the French general population.
  
  
  RESULTS
  A total of 326 beta-blocker users and 513 users of other treatments were included in the cohort. During the follow-up period, representing 8,466 person-years, incident cancer cases were 15 and 59 in beta-blocker ever-users versus never-users, respectively. Using the Cox model, the overall relative risk of cancer was 0.51 (95% confidence interval [95% CI]: 0.29-0.90) in the beta-blocker ever-users versus never-users (p=0.02), with a 6% decrease per year of use (95% CI: 1%-12%; p=0.03). The corresponding SIR ratio between these two groups was 0.44 (95% CI: 0.24-0.76).
  
  
  CONCLUSIONS
  In this cohort, the beta-blocker treatments appeared to decrease the cancer risk significantly. However, this result should be considered with caution; further work is needed, as some sources of bias associated with this type of epidemiological study cannot be totally excluded.
authors.affiliation: Service de Cardiologie et Médecine Interne, Hôpital Privé des Diaconesses, 18, rue du Sergent-Bauchat, 75012 Paris. malgazi@noos.fr
authors.forename: M
authors.initials: M
authors.lastname: Algazi
authors.forename: G
authors.initials: G
authors.lastname: Plu-Bureau
authors.forename: A
authors.initials: A
authors.lastname: Flahault
authors.forename: M-G
authors.initials: MG
authors.lastname: Dondon
authors.forename: M G
authors.initials: MG
authors.lastname: Lê
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use*; D000367:Age Factors; D000368:Aged; D000818:Animals; D015331:Cohort Studies; D005260:Female; D005500:Follow-Up Studies; D005602:France / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000453:epidemiology*; D009765:Obesity / Q000150:complications; D016016:Proportional Hazards Models; D011446:Prospective Studies; D012306:Risk; D012307:Risk Factors; D012737:Sex Factors; D012907:Smoking / Q000009:adverse effects; D013997:Time Factors
chemical_list: D000319:Adrenergic beta-Antagonists